基于CRISPR转录激活系统构建内源性着丝粒蛋白F稳定过表达的肝细胞癌细胞模型
作者:
基金项目:

国家自然科学基金(81602032,81071973);国家科技重大专项课题(2017ZX10201201007002)


Construction of a stable centromere protein F overexpression cell model of hepatocellular carcinoma using CRISPR activation system
Author:
  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献 [21]
  • |
  • 相似文献
  • |
  • 引证文献
  • | |
  • 文章评论
    摘要:

    临床研究表明着丝粒蛋白F (centromere protein F, CENPF)与肝细胞癌(hepatocellular carcinoma, HCC)的发生相关。由于CENPF蛋白的分子量高达358 kDa,目前有关CENPF致癌机制研究使用的体内外模型主要基于CENPF表达敲低,尚缺乏将CENPF过表达以探究其与癌变因果关系的研究,CENPF过表达改变到底是“因”还是“果”仍不清楚。本研究旨在利用包括lentiMPHv2和lentiSAMv2两个载体的CRISPR/dCas9转录激活协同激活介体(synergistic activation mediator, SAM)系统构建内源性CENPF稳定过表达的细胞模型,为阐明CENPF过表达与HCC发生发展的因果关系提供有效工具。首先设计并合成能够特异性识别CENPF基因转录起始位点的单向导核糖核酸(single guide RNAs, sgRNA),并将其插入lentiSAMv2质粒中。利用慢病毒载体将lentiMPHv2质粒导入Huh-7和HCCLM3细胞株中,用潮霉素B筛选后再用慢病毒载体将连接好的携带sgRNA序列的lentiSAMv2质粒导入细胞中,并用杀稻瘟菌素S继续筛选。对2种抗生素筛选获得的Huh-7和HCCLM3细胞株样品进行CENPF mRNA和蛋白表达水平的检测,结果显示sgRNA1和sgRNA4序列均能够激活内源CENPF的表达,其中sgRNA4诱导转录效果更加明显。本研究利用CRISPR/dCas9系统成功构建内源性CENPF稳定过表达的HCC细胞模型,为研究CENPF过表达与肿瘤发生的因果关系奠定基础,并为构建大分子量蛋白过表达的细胞模型提供参考方案。

    Abstract:

    Current studies have shown that centromere protein F (CENPF) was overexpressed in hepatocellular carcinoma (HCC) and might be involved in the pathogenesis of HCC. Specifically, due to the very large molecular weight (358 kDa) of CENPF full length protein, only CENPF knock-down, but not overexpression models, were applied currently to explore the carcinogenicity of CENPF in HCC. Whether CENPF overexpression is a cause or an effect in HCC remains to be illustrated. We aimed to establish a CENPF overexpression cell model using CRISPR/dCas9 synergistic activation mediator (SAM) system with lentiMPHv2 and lentiSAMv2 vectors to explore the role of CENPF overexpression in HCC. Single guide RNAs (sgRNAs) that specifically identify the transcription initiation site of CENPF gene were synthesized and inserted into the lentiSAMv2 plasmid. Huh-7 and HCCLM3 cells were first transduced with lentiMPHv2 and then selected with hygromycin B. The cells were then transduced with lentiSAMv2 carrying specific sgRNA for CENPF gene, followed by blasticidin S selection. The mRNA and protein detection results of Huh-7 and HCCLM3 cells screened by hygromycin B and blasticidin S showed that the endogenous overexpression of CENPF can be induced by sgRNA1 and sgRNA4, especially by sgRNA4. By using the CRISPR/dCas9 technique, stable cell models with overexpressed CENPF were successfully constructed to explore the role of CENPF in tumorigenesis, which provides a reference for the construction of cell models overexpressing large molecular weight protein.

    参考文献
    [1] HUANG YG, LI D, WANG L, SU XM, TANG XB. CENPF/CDK1 signaling pathway enhances the progression of adrenocortical carcinoma by regulating the G2/M-phase cell cycle[J]. Journal of Translational Medicine, 2022, 20(1):78.
    [2] CHEN EB, QIN X, PENG K, LI Q, TANG C, WEI YC, YU S, GAN L, LIU TS. HnRNPR-CCNB1/CENPF axis contributes to gastric cancer proliferation and metastasis[J]. Aging, 2019, 11(18):7473-7491.
    [3] LIN SC, KAO CY, LEE HJ, CREIGHTON CJ, ITTMANN MM, TSAI SJ, TSAI SY, TSAI MJ. Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer[J]. Nature Communications, 2016, 7:11418.
    [4] CHEN Q, XU HC, ZHU J, FENG KH, HU CL. LncRNA MCM3AP-AS1 promotes breast cancer progression via modulating miR-28-5p/CENPF axis[J]. Biomedicine & Pharmacotherapy, 2020, 128:110289.
    [5] CHEN HJ, WU FB, XU HJ, WEI GQ, DING M, XU FG, DEIVASIGAMANI A, ZHOU GR, HUI KM, XIA HP. Centromere protein F promotes progression of hepatocellular carcinoma through ERK and cell cycle-associated pathways[J]. Cancer Gene Therapy, 2022, 29(7):1033-1042.
    [6] HONG Y, LONG J, LI H, CHEN SH, LIU QQ, ZHANG B, HE XM, WANG Y, LI HY, LI YM, ZHANG T, LU CZ, YAN H, ZHANG ML, LI Q, CAO BW, BAI ZG, WANG J, ZHANG ZT, ZHU ST, et al. An analysis of immunoreactive signatures in early stage hepatocellular carcinoma[J]. EBioMedicine, 2015, 2(5):438-446.
    [7] LI XJ, LI YM, XU AJ, ZHOU DH, ZHANG B, QI SP, CHEN ZB, WANG XM, OU XJ, CAO BW, QU CF, HUANG J. Apoptosis-induced translocation of centromere protein F in its corresponding autoantibody production in hepatocellular carcinoma[J]. OncoImmunology, 2021, 10(1):1992104.
    [8] WANG SW, GAO C, ZHENG YM, YI L, LU JC, HUANG XY, CAI JB, ZHANG PF, CUI YH, KE AW. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer[J]. Molecular Cancer, 2022, 21(1):57.
    [9] GILBERT LA, LARSON MH, MORSUT L, LIU ZR, BRAR GA, TORRES SE, STERN-GINOSSAR N, BRANDMAN O, WHITEHEAD EH, DOUDNA JA, LIM WA, WEISSMAN JS, QI LS. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes[J]. Cell, 2013, 154(2):442-451.
    [10] PEREZ-PINERA P, DEWRAN KOCAK D, VOCKLEY CM, ADLER AF, KABADI AM, POLSTEIN LR, THAKORE PI, GLASS KA, OUSTEROUT DG, LEONG KW, GUILAK F, CRAWFORD GE, REDDY TE, GERSBACH CA. RNA-guided gene activation by CRISPR-Cas9-based transcription factors[J]. Nature Methods, 2013, 10(10):973-976.
    [11] TANENBAUM ME, GILBERT LA, QI LS, WEISSMAN JS, VALE RD. A protein-tagging system for signal amplification in gene expression and fluorescence imaging[J]. Cell, 2014, 159(3):635-646.
    [12] JOUNG J, KONERMANN S, GOOTENBERG JS, ABUDAYYEH OO, PLATT RJ, BRIGHAM MD, SANJANA NE, ZHANG F. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening[J]. Nature Protocols, 2017, 12(4):828-863.
    [13] BÖHM S, SPLITH V, RIEDMAYR LM, DOMINIK RÖTZER R, GASPARONI G, NORDSTRÖM KJV, ELISABETH WAGNER J, HINRICHSMEYER KS, WALTER J, WAHL-SCHOTT C, FENSKE S, BIEL M, MICHALAKIS S, BECIROVIC E. A gene therapy for inherited blindness using dCas9-VPR-mediated transcriptional activation[J]. Science Advances, 2020, 6(34):eaba5614.
    [14] LI ZX, ZHANG DD, XIONG XY, YAN BY, XIE W, SHEEN J, LI JF. A potent Cas9-derived gene activator for plant and mammalian cells[J]. Nature Plants, 2017, 3(12):930-936.
    [15] KONERMANN S, BRIGHAM MD, TREVINO AE, JOUNG J, ABUDAYYEH OO, BARCENA C, HSU PD, HABIB N, GOOTENBERG JS, NISHIMASU H, NUREKI O, ZHANG F. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex[J]. Nature, 2015, 517(7536):583-588.
    [16] DAI MO, YAN G, WANG N, DALIAH G, EDICK AM, POULET S, BOUDREAULT J, ALI S, BURGOS SA, LEBRUN JJ. In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy[J]. Nature Communications, 2021, 12:3055.
    [17] SUN JB, HUANG JZ, LAN J, ZHOU K, GAO Y, SONG ZG, DENG YY, LIU LX, DONG Y, LIU LX. Overexpression of CENPF correlates with poor prognosis and tumor bone metastasis in breast cancer[J]. Cancer Cell Int, 2019, 19:264.
    [18] HUANG YG, CHEN XW, WANG L, WANG TY, TANG XB, SU XM. Centromere protein F (CENPF) serves as a potential prognostic biomarker and target for human hepatocellular carcinoma[J]. Journal of Cancer, 2021, 12(10):2933-2951.
    [19] YANG X, MIAO BS, WEI CY, DONG RZ, GAO PT, ZHANG XY, LU JC, GAO C, WANG XY, SUN HC, ZHOU J, FAN J, KE AW, SHI GM, CAI JB. Lymphoid-specific helicase promotes the growth and invasion of hepatocellular carcinoma by transcriptional regulation of centromere protein F expression[J]. Cancer Science, 2019, 110(7):2133-2144.
    [20] DAI YD, LIU LL, ZENG TT, ZHU YH, LI JC, CHEN LL, LI Y, YUAN YF, MA S, GUAN XY. Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma[J]. Biochemical and Biophysical Research Communications, 2013, 436(4):711-718.
    [21] KIM HE, KIM DG, LEE KJ, SON JG, SONG MY, PARK YM, KIM JJ, CHO SW, CHI SG, CHEONG HS, DOO SHIN H, LEE SW, LEE JK. Frequent amplification of CENPF, GMNN and CDK13 genes in hepatocellular carcinomas[J]. PLoS One, 2012, 7(8):e43223.
    相似文献
    引证文献
引用本文

齐赛平,李潇瑾,周冬虎,黄坚. 基于CRISPR转录激活系统构建内源性着丝粒蛋白F稳定过表达的肝细胞癌细胞模型[J]. 生物工程学报, 2023, 39(9): 3738-3746

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2022-08-18
  • 录用日期:2023-03-17
  • 在线发布日期: 2023-09-28
  • 出版日期: 2023-09-25
文章二维码
您是第5998212位访问者
生物工程学报 ® 2025 版权所有

通信地址:中国科学院微生物研究所    邮编:100101

电话:010-64807509   E-mail:cjb@im.ac.cn

技术支持:北京勤云科技发展有限公司